Clinical trial
Pazopanib in Treating Patients With Recurrent Glioblastoma
NCT00459381 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00459381 |
|---|---|
| Title | Pazopanib in Treating Patients With Recurrent Glioblastoma |
| Official title | A Phase II Trial of GW786034 (Pazopanib) in Patients With Recurrent Glioblastoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor |
| Intervention type | Drug, Other |
| Interventions | pazopanib hydrochloride, laboratory biomarker analysis |
| Enrollment | 35 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Apr 11, 2007 |
| Last update posted | Mar 15, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: